Based on animal studies, may impair fertility. Advise females and males of the adverse reproductive potential of lonafarnib.
- TRADE NAMES: SCH 663366; Zokinvy (Eiger Biopharmaceuticals)
- INDICATIONS:
Reduction of the risk of mortality in Hutchinson-Gilford Progeria Syndrome. For treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations.
- CLASS: Farnesyltransferase inhibitor
- HALF-LIFE: approximately 4–6 hours
- FDA APPROVAL DATE: 11/20/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atorvastatin, CYP2C9 inhibitors, CYP3A inducers, CYP3A inhibitors, Grapefruit Juice, Loperamide, Lovastatin, Midazolam, Simvastatin - PREGNANCY: Can cause fetal harm. Advise females of reproductive potential of the risk to a fetus and to use effective contraception.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
